Sector Alpha Week of 2026-08-05
Sector Alpha — machine-written from the numbers · Data as of 2026-08-05

Corebridge Financial, Inc.

CRBG
Financials · Asset Management

Corebridge Financial, Inc.'s three tracks disagree. Price, valuation and the earnings engine each tell a different story — the next quarter or two settles it.

The sharpest disagreement: the price moved −8.4% in a year while annual EPS moved −118.3% — the difference is re-rating, and re-rating has to be repaid with earnings.

The price is topping out (6 weeks in) while the P/BV sits at the 52nd percentile of its own 4-year range. Underneath, the last four quarters read improving, with the the net margin at −1.5%. What settles it: whether earnings grow into a price that has already moved.

Stage
Deteriorating
fundamental trajectory, 12 quarters
Price
$31.6
−8.4% 1Y
P/BV
1.4×
52nd pctile
of its own 4-year range
Revenue (Mar 26)
$4.0 B
+10.9% YoY
Profit (Mar 26)
$−0.1 B
Net margin
−1.5%
+17.0 pp YoY
ROE
2%
FY25
ROA
0.20%
latest
01 · Price story

Price story Before the numbers, the tape. A stock price moves through four repeating seasons: a flat base (stage 1), an advance (2), a top (3), a decline (4). Where the price sits in that cycle frames everything below.

Corebridge Financial, Inc. trades at $31.6, losing momentum at the top and 6 weeks into that stage. That is +10.0% against its own 200-day average. It sits at 73% of a 52-week range of $22 to $35. On relative strength it has been ahead of the S&P 500 on a trailing-13-week view for 9 straight weeks.

Today the stock is losing momentum at the top — week 6 of stage 3. At $31.6 it trades +10.0% versus its 200-day average and sits at 73% of its 52-week range ($22–$35).

Aug 26: $31.6 Weekly closing price ($) with 50- and 200-day averages; shaded bands mark the price stage (grey base, green advance, amber top, red decline). 3-year window.
+10.0% versus the 200-day line, week 6 of stage 3
Price50-day avg200-day avg
S2S2S1S4$37.3$32.0$26.7$21.5$16.2$$32$29Jul 23Apr 24Jan 25Oct 25Aug 26
S2S2S1S4$37.3$32.0$26.7$21.5$16.2$$32$29Jul 23Jan 25Aug 26
Beating or trailing, week by week since 2022 Each cell is one week from 2022 to now (204 weeks): the stock's trailing 13-week return minus the S&P 500's, green ahead / red behind (±25% ramp). Grey cells are the 13-week warm-up or weeks where the S&P 500 reading is not held.
trailing 13-week return vs the S&P 500
Sep 22Aug 26

Against the market, two honest reads. Cumulative: over the last 3.9 years the stock moved +53% while the S&P 500 moved +100% — behind the index over the full window. Recent form: on a trailing-13-week view the stock has been ahead for 9 straight weeks — the ribbon below is that same metric, week by week.

What would end the trend, mechanically: two Friday closes in a row below the 200-day line. That is the exit rule — no debates.

02 · Valuation

Valuation For a bank we price the book, not the earnings: P/BV is what the market pays for each $1 of the bank's net worth. A bank below 1× book is priced below the value of what it owns, net of what it owes.

Corebridge Financial, Inc. trades at 1.4× P/BV, mid-range by its own standards (52nd percentile). Its long-run median P/BV is 1.4×, measured across 3.9 years of weekly readings. This places the multiple against the stock’s own record, and says nothing about what the business is worth.

Today's P/BV of 1.4× is mid-range by its own standards (52nd percentile), against a long-run median of 1.4× measured over 3.9 years of weekly readings. This is a comparison against the stock's own history — not a claim about what it is worth.

The honest context for that discount: a bank earning about 2% on its equity is worth less per dollar of book, and the market has priced that in rather than overlooked it. The discount closes only if the returns themselves improve.

P/BV 1.4× vs a 1.4× long-run median P/BV, weekly (left axis); book value per share, quarterly steps drawn weekly (right axis). 3.9-year window; brief peaks above 1.9× shown pinned at the top. The book value / share bars are red where the reading is lower than the quarter before.
mid-range by its own standards (52nd percentile)
P/BVMedianBook value / share (quarterly)
2.0×$28.01.7×$21.01.4×$14.01.1×$7.00.8×$0.0×$1.38×$23Sep 22Sep 23Aug 24Aug 25Aug 26
2.0×$28.01.7×$21.01.4×$14.01.1×$7.00.8×$0.0×$1.38×$23Sep 22Aug 24Aug 26
PEG 0.38 PEG ratio per quarter — the P/E divided by the earnings-growth rate. The dashed line marks 1.0: below it the growth is cheap against the multiple, above it the price already prices the growth in. Last 14 quarters.
below 1.0, the growth looks cheap against the multiple
PEGPEG = 1.0
1.1×0.9×0.6×0.4×0.1××0.38×Dec 22Sep 23Jun 24Mar 25Mar 26
1.1×0.9×0.6×0.4×0.1××0.38×Dec 22Jun 24Mar 26
P/BV
1.4×
52nd percentile of 4y
PEG
0.35
as reported

🚨 Why the multiple sits where it does: over the past year book value grew while the price moved −8.4% — price and book moved together, holding the multiple in its range.

The price move, decomposed: over 3y, of the +17.5%/yr price move, ~+12.1%/yr came from book-value growth and ~+5.4 pp from the multiple (expanding). The split is the honest approximate (price return minus book-value growth); it makes the rally itself visible instead of hiding it behind the percentile.

Put together: the multiple is unremarkable against its own past, so the story rests on the book-value line underneath it, not the multiple.

03 · Stage: Deteriorating

Stage: Deteriorating Every business sits somewhere on a fundamental arc, and this page names the spot before anything else. The last twelve quarters of revenue, profit and EPS growth — plus the return the business earns on its capital — are read as curves: Deteriorating (the curves are falling), Turning around (a trough has just formed and the last few quarters lift off it), Improving (the climb off the trough is sustained), Consistent (steadily positive with healthy returns), Topping out (still high but decelerating from the peak). When the curves genuinely disagree the read is Mixed; too little history is No read. CAGR (compound annual growth rate) is the smooth yearly pace that turns the starting value into the latest one — the fairest way to compare growth across different time spans. Read the columns together: if the 1-year number towers over the 10-year, recent growth is running hotter than the long-run trend. A dash means that window is not held, or the base year was a loss (where a growth rate is not meaningful).

Corebridge Financial, Inc. reads as deteriorating on its fundamental arc. Deteriorating — profit and EPS growth are shrinking (profit growth −70.4% latest against +111.5% at its 12-quarter best), ROE holding at 1.8%. The read is built from 12 quarters across 4 curves, on full evidence.

Growth, year by year: revenue −1.2% in FY25, profit −117.7% Year-over-year growth per fiscal year, %: revenue (left axis); net profit and EPS (right axis — profit growth swings far wider). Zero line drawn.
Revenue YoYProfit YoYEPS YoY
8.6%136%0.0%68%−8.8%0.0%−18%−69%−26%−137%%%−1.2%−117.7%FY21FY23FY25
8.6%136%0.0%68%−8.8%0.0%−18%−69%−26%−137%%%−1.2%−117.7%FY21FY23FY25
Three growth curves, twelve quarters Year-on-year growth of trailing-twelve-month revenue (left axis), profit and EPS (right axis — they swing far wider), % at each quarter-end. A missing point means that reading is not held for the quarter.
the trajectory the stage is read from · revenue accelerating, profit stabilising
RevenueProfitEPS
23%147%9.0%64%−4.6%−19%−18%−102%−32%−184%%%14.6%−70.4%−63.6%Jun 23Sep 24Mar 26
23%147%9.0%64%−4.6%−19%−18%−102%−32%−184%%%14.6%−70.4%−63.6%Jun 23Sep 24Mar 26
ROE Trailing-twelve-month net profit as a share of quarter-end equity, %.
the return curve, computed quarterly
ROE
26%17%7.3%−2.3%−12%%1.8%Jun 23Dec 23Sep 24Jun 25Mar 26
26%17%7.3%−2.3%−12%%1.8%Jun 23Sep 24Mar 26
Revenue growth
Flat
latest +14.6% · span −28.0% to +18.8%
Profit growth
Stuck low
latest −70.4% · span −161.4% to +111.5%
EPS growth
Stuck low
latest −63.6% · span −160.8% to +123.7%
ROE
Stuck low
latest 1.8% · span −9.3%–23.8%

🚨 Why it matters: falling curves mean every cheap-looking ratio below needs a discount for direction.

Compound annual growth rate (%) Compound annual growth rate over each window, %. Revenue, profit and EPS from fiscal-year figures; stock price is the price CAGR over the same spans. A dash = that window is not held, or the base was a loss.
1yr3yr5yr10yr
Revenue−1.2%−9.2%
Stock price−8.4%+17.5%
Revenue YoY (Mar 26)
+10.9%
latest quarter vs a year ago
Revenue 10y
−5.6%
long-run compound pace
04 · 4-Factor Sector Score

4-Factor Sector Score

44.7/100 — rank 15 of 29 in Asset Management · 55% evidence confidence

Corebridge Financial, Inc. scores 44.7 out of 100 against the 29 companies it is compared with in Asset Management, ranking 15. Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.

The four contributions add to the total exactly: 19.1 + 5.2 + 9.8 + 10.6 = 44.7. This is the SAME number shown on the sector comparison — it is computed once, for the whole peer set, and read here.

What would change it: The read weakens if ROA rolls over or gross NPA rises while sector-relative strength deteriorates.

05 · Revenue

Revenue For a bank, revenue is everything the franchise earns — interest on the loan book plus fees from its businesses.

Corebridge Financial, Inc. reported $4.0 B of income in the Mar 26 quarter, +10.9% year on year. That is the 3rd straight quarter of year-on-year growth. Over 4 years it has compounded at −5.6% a year. The last full year, FY25, came in at $18.5 B. The last four reported quarters add to $18.9 B.

FY25 revenue came in at $18.5 B (−1.2% on the year), capping 4 years at −5.6% compound. The latest quarter (Mar 26) printed $4.0 B, +10.9% year on year — the 3rd consecutive quarter of year-over-year growth.

FY25 revenue $18.5 B (−1.2% YoY) Revenue bars, $ B (left); YoY growth-% line (right). 5-year window. A bar is red when it is lower than the year before.
−5.6% a year over 4 years
RevenueYoY growth
278.6%200.0%13−8.8%6.7−18%0.0−26%$ B%$19B−1.2%FY21FY23FY25
278.6%200.0%13−8.8%6.7−18%0.0−26%$ B%$19B−1.2%FY21FY23FY25
Mar 26: $4.0 B (+10.9% YoY) Quarterly revenue bars, $ B (left); YoY growth-% line (right). Last 12 quarters. A bar is red when it is lower than the quarter before.
3rd straight quarter of growth
Revenue (quarterly)YoY growth
7.3121%5.575%3.728%1.8−19%0.0−66%$ B%$4B10.9%Jun 23Sep 24Mar 26
7.3121%5.575%3.728%1.8−19%0.0−66%$ B%$4B10.9%Jun 23Sep 24Mar 26

Pace check: the last four quarters averaged +24.0% growth against the decade's −5.6% — the current year is running faster than its own long-run rate.

Acceleration check: trailing-twelve-month revenue grew +14.6% over the last 4 quarters against −3.7%/yr over the last 8 — accelerating; TTM profit −70.4% vs −69.9%/yr — stabilising.

06 · Net margin

Net margin Net margin — what the bank keeps of every $100 of revenue after every cost, provision and tax. With big fee businesses in the mix, it is the cleanest margin we can read for this bank.

Corebridge Financial, Inc.'s net margin is −1.5% in the Mar 26 quarter, +17.0 percentage points against the same quarter a year ago. Across 5 fiscal years the net margin has ranged −2.1% to 39.4%. The current quarter sits inside that band.

The latest quarter's net margin is −1.5%, +17.0 pp against the same quarter a year ago. Across 5 fiscal years the net margin has ranged −2.1%–39.4%.

Why: the numbers show the net margin move clearly, but the cost lines behind it sit below what we hold — so we state the move without inventing its driver.

FY25: −2.1% Net margin by fiscal year, %, line (left); year-on-year change in the margin, in percentage points, line (right). 5-year window.
within a −2.1–39.4% band over 5 years
net marginYoY change (pp)
43%9.1%31%−1.1%19%−11%6.6%−21%−5.4%−32%%%−2.1%−13.9%FY21FY23FY25
43%9.1%31%−1.1%19%−11%6.6%−21%−5.4%−32%%%−2.1%−13.9%FY21FY23FY25
Mar 26: −1.5% net margin (+17.0 pp YoY) Quarterly net margin, %, line (left); year-on-year change in the margin, in percentage points, line (right). Last 12 quarters. Net profit as a share of total revenue, per quarter.
Net marginYoY change (pp)
44%87%20%41%−4.1%−4.7%−28%−50%−52%−96%%%−1.5%17%Jun 23Sep 24Mar 26
44%87%20%41%−4.1%−4.7%−28%−50%−52%−96%%%−1.5%17%Jun 23Sep 24Mar 26
07 · Net profit

Net profit Net profit is what survives every cost, interest and tax — the number EPS, dividends and book value all grow from.

Corebridge Financial, Inc. posted a net loss of $0.1 B in the Mar 26 quarter. The full FY25 year was a loss of $0.4 B. That loss is 1.5% of the quarter's revenue. The same quarter a year earlier lost $0.7 B. 5 of the last 12 reported quarters were loss-making.

Mar 26 profit was $−0.1 B, null year on year. On the full year, FY25 printed $−0.4 B (−117.7%).

FY25 profit $−0.4 B (−117.7% YoY) Net profit bars, $ B (left); YoY growth-% line (right). 5-year window. A bar is red when it is lower than the year before.
Net profitYoY growth
9.9130%7.263%4.4−3.1%1.6−70%−1.2−136%$ B%$−0B−117.7%FY21FY23FY25
9.9130%7.263%4.4−3.1%1.6−70%−1.2−136%$ B%$−0B−117.7%FY21FY23FY25
Mar 26: $−0.1 B (null YoY) Quarterly net profit bars, $ B (left); YoY growth-% line (right). Last 12 quarters. A bar is red when it is lower than the quarter before.
Net profit (quarterly)YoY growth
2.54.1%1.5−77%0.4−158%−0.6−239%−1.6−319%$ B%$−0B−64%Jun 23Sep 24Mar 26
2.54.1%1.5−77%0.4−158%−0.6−239%−1.6−319%$ B%$−0B−64%Jun 23Sep 24Mar 26
08 · Asset quality — the ladder

Asset quality — the ladder Gross NPA is the slice of the loan book where repayments have stopped. Net NPA is what remains after the money already set aside against those loans. Falling is healing; rising is damage arriving.

Loan-book quality history is not available for Corebridge Financial, Inc., so this section names the gap rather than estimating a ratio. No gross or net non-performing-asset series is filed in a form this page can read, and none is inferred from the profit line. The income, margin and return sections above carry the evidence this business does report.

We do not hold quarterly loan-book quality numbers for this bank, so this section states that plainly rather than working around it.

Why: loan-book quality is the engine room of a bank, and its drivers — slippages, recoveries, provisioning — sit below what we hold for this name; the sections around it carry the reads we can stand behind.

09 · The loan book

The loan book We read the loan book through revenue — when the book and the businesses grow, revenue grows with them. It is a rough proxy, and we say so: rate moves and fee swings can shift it a few points in any one year.

Corebridge Financial, Inc.'s revenue grew −1.2% in FY25 to $18.5 B, so the book is flat. The latest quarter ran +10.9% year on year. The net margin on that income is −1.5%, +17.0 percentage points against a year ago. Interest income is a proxy for the book; rate moves can shift it a few points in any one year.

FY25 revenue was $18.5 B, −1.2% on the year, and the latest quarter ran +10.9% year on year. The net margin on that revenue is −1.5% this quarter (+17.0 pp YoY) — growth with a widening margin on it.

FY25: revenue $18.5 B (−1.2% YoY) with the net margin at −2.1% Revenue by fiscal year, $ B (bars, left); net margin, % (line, right). 5-year window. A bar is red when it is lower than the year before.
RevenueNet margin
2743%2031%1319%6.76.6%0.0−5.4%$ B%$19B−2.1%FY21FY22FY23FY24FY25
2743%2031%1319%6.76.6%0.0−5.4%$ B%$19B−2.1%FY21FY23FY25

The synthesis: a lender compounds when the book grows while the margin holds and the loan book stays clean — with quarterly loan-quality numbers missing here, revenue growth and margin are the two we watch.

10 · Returns on equity and assets

Returns on equity and assets Two numbers rate a bank: ROE — what it earns on shareholder money — and ROA — what it earns on everything it deploys. ROE above ~13–15% earns its keep; below that, growth builds book slowly.

Corebridge Financial, Inc. earns a return on equity of −3% in FY25. Its trough over the ladder below was −3% in FY25. On the asset side every $100 of the balance sheet earned about $0.20, which is the return before leverage is applied.

FY25 ROE came in at −3%. On assets, the latest reading is about 0.20% — every $100 the bank deploys earns roughly $0.20 a year. That return is below the bar a bank must clear to compound book value quickly — which is also the honest reason the stock trades where it does.

FY25: ROE −3%, ROA 0.00% Return on equity by fiscal year, % (line, left); return on assets, % (line, right). 5-year window. A lender is judged on ROE and ROA — return on invested capital does not apply to a bank.
the full ladder
ROEROA
89%2.5%64%1.8%40%1.1%15%0.5%−9.6%−0.2%%%−2.8%0%FY21FY23FY25
89%2.5%64%1.8%40%1.1%15%0.5%−9.6%−0.2%%%−2.8%0%FY21FY23FY25
Mar 26: ROE −0.5% (TTM), ROA 0.10% Trailing-twelve-month return on equity (left) and on assets (right), per quarter, %. Last 12 quarters, anchored to the annual figure.
ROE (TTM)ROA (TTM)
26%0.9%16%0.5%5.9%0.1%−4.2%−0.3%−14%−0.7%%%−0.5%0.1%Jun 23Sep 24Mar 26
26%0.9%16%0.5%5.9%0.1%−4.2%−0.3%−14%−0.7%%%−0.5%0.1%Jun 23Sep 24Mar 26

Why: the ROE ladder shows the move; the deposit-cost and provisioning drivers behind it sit below what we hold.

11 · Dividend

Dividend A dividend is cash paid out per share. Dividend per share is the declared amount for the period; the trailing twelve-month total is the four most recent quarters added together.

Corebridge Financial, Inc. paid $0.97 per share over the last four reported quarters, up 4.2% on a year ago. The most recent declaration was $0.25 for Mar 26. Against the current price of $31.6 that is a trailing yield of 3.07%, measured on dividends already paid rather than on a forecast.

Corebridge Financial, Inc. paid $0.97 per share across the last four reported quarters, most recently $0.25 for Mar 26. That is up 4.2% against the same quarter a year earlier. Against the current price of $31.6 the trailing twelve months work out to 3.07% — trailing dividends measured against today's price, not a forward estimate.

Dividend per share by quarter Declared dividend per share, $ B, per reported quarter. 12 quarters on file.
latest $0.25 (Mar 26)
Dividend per share
0.270.200.140.070.00$ B$0BJun 23Dec 23Sep 24Jun 25Mar 26
0.270.200.140.070.00$ B$0BJun 23Sep 24Mar 26
12 · Debt

Debt

For a bank, borrowings are raw material, not a warning sign — solvency is read through the returns and the loan book. A manufacturer’s debt is a claim against its profits, so the debt-to-equity lens that works everywhere else misleads on a lender and is not applied here.

A manufacturer’s debt is a claim against its profits; a bank’s borrowings are its inventory — money taken in to be lent out. The debt lens that works everywhere else misleads here, so this page does not apply it. The solvency questions for a bank — is the loan book sound, is the equity earning — are read through the loan-book and returns sections above.

13 · Ownership

Ownership There is no quarter-by-quarter holder register to read here, so we read the crowd through short interest — the slice of tradable shares currently sold short, positioned for a fall.

8.0% of Corebridge Financial, Inc.'s tradable float is currently sold short — some money is positioned against it. At typical trading volumes those positions would take about 4.5 days to buy back. There is no quarter-by-quarter holder register to read for this filer, so the crowd is read through short interest instead.

The latest reading: 8.0% of the float is sold short, and at typical trading volumes it would take about 4.5 days to buy those positions back. Some money is positioned against it. This is a single point-in-time reading — we do not yet hold its history, so we show no trend chart.

Short interest
8.0%
of the tradable float
Days to cover
4.5
at typical volumes

Why it sits there: who is doing the shorting, and why, does not travel with the number — the level is shown without inventing its story.

14 · Safety line

Safety line The Z-score estimates how far a company sits from balance-sheet distress — above roughly 3 is safe, below roughly 1.8 is the danger zone. It was built for manufacturers, so it is not applied to banks and lenders.

Corebridge Financial, Inc.: the Z-score is omitted — it was built for manufacturers, not banks, and applying it here would be theatre. The Z-score was built for manufacturers and is not applied to banks and lenders, so solvency here is read from the capital and asset-quality lines instead.

The safety line in one sentence: the Z-score is omitted — it was built for manufacturers, not banks, and applying it here would be theatre.

15 · Related companies · Asset Management
CompanyScorePrice stageGrowth & earnings/35Capital efficiency/25Valuation/20Relative strength/20
1Victory Capital Holdings, Inc.VCTR 66.2/100Favorable setup76% evidence LEADER 24.7/35 Income 64.1% · PAT 29.1% 71% evidence 16.5/25 ROA 3.6% · ROE 6.4% · GNPA — 68% evidence 7.9/20 P/BV 2.29× · P/BV÷ROE 0.36 70% evidence 17.1/20 RS sector 21% · RS bench 25.6% · 1Y 45.6%12 of 12 weeks ahead 100% evidence
Exact sum: 24.7 + 16.5 + 7.9 + 17.1 = 66.2 · Decision use: Confirmed research leader: earnings, capital efficiency and relative strength agree. Move to management, catalyst and risk diligence.
2Raymond James Financial, Inc.RJF 59.0/100Mixed-positive evidence60% evidence BREAKING OUT 21.3/35 Income — · PAT — 26% evidence 15.3/25 ROA 1.4% · ROE 9.7% · GNPA — 68% evidence 11.0/20 P/BV 2.24× · P/BV÷ROE 0.23 70% evidence 11.4/20 RS sector -3.3% · RS bench 0% · 1Y 8.3%4 of 12 weeks ahead 100% evidence
Exact sum: 21.3 + 15.3 + 11 + 11.4 = 59 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
3Affiliated Managers Group, Inc.AMG 57.8/100Mixed-positive evidence60% evidence BREAKING OUT 20.1/35 Income — · PAT — 26% evidence 14.6/25 ROA 1.6% · ROE 6.1% · GNPA — 68% evidence 6.9/20 P/BV 2.94× · P/BV÷ROE 0.48 70% evidence 16.2/20 RS sector 14.9% · RS bench 19.4% · 1Y 81.5%10 of 12 weeks ahead 100% evidence
Exact sum: 20.1 + 14.6 + 6.9 + 16.2 = 57.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
4SEI Investments CompanySEIC 56.7/100Mixed-positive evidence60% evidence BREAKING OUT 17.9/35 Income — · PAT — 26% evidence 17.6/25 ROA 5.2% · ROE 7.7% · GNPA — 68% evidence 5.9/20 P/BV 4.21× · P/BV÷ROE 0.55 70% evidence 15.3/20 RS sector 5.7% · RS bench 9.5% · 1Y 19.7%6 of 12 weeks ahead 100% evidence
Exact sum: 17.9 + 17.6 + 5.9 + 15.3 = 56.7 · Decision use: Strong business, demanding price: keep it on the quality list, but require either earnings upgrades or valuation compression.
5BlackRock, Inc.BLK 53.3/100Mixed-positive evidence80% evidence BASING 22.9/35 Income 26.5% · PAT 9.2% 81% evidence 16.4/25 ROA 2.5% · ROE 7.9% · GNPA — 68% evidence 8.4/20 P/BV 2.64× · P/BV÷ROE 0.33 70% evidence 5.6/20 RS sector -8.3% · RS bench -5.1% · 1Y 0.5%0 of 12 weeks ahead 100% evidence
Exact sum: 22.9 + 16.4 + 8.4 + 5.6 = 53.3 · Decision use: Acceleration candidate, not a confirmed leader: earnings are strong but sector-relative strength is -8.3% and the one-year return is 0.5%. Do not upgrade until sector-relative strength is above zero and another reported period confirms growth.
6Blackstone Inc.BX 50.6/100Mixed-positive evidence60% evidence TURNING 20.8/35 Income — · PAT — 26% evidence 18.1/25 ROA 5% · ROE 10.8% · GNPA — 68% evidence 4.4/20 P/BV 9.7× · P/BV÷ROE 0.9 70% evidence 7.3/20 RS sector -14.2% · RS bench -11.8% · 1Y -18.8%1 of 12 weeks ahead 100% evidence
Exact sum: 20.8 + 18.1 + 4.4 + 7.3 = 50.6 · Decision use: Strong business, demanding price: keep it on the quality list, but require either earnings upgrades or valuation compression.
7State Street CorporationSTT 50.3/100Mixed-positive evidence60% evidence LEADER 17.7/35 Income — · PAT — 26% evidence 9.3/25 ROA 0.3% · ROE 3.9% · GNPA — 68% evidence 7.1/20 P/BV 1.66× · P/BV÷ROE 0.43 70% evidence 16.2/20 RS sector 18.2% · RS bench 23% · 1Y 66.8%12 of 12 weeks ahead 100% evidence
Exact sum: 17.7 + 9.3 + 7.1 + 16.2 = 50.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
8Janus Henderson Group plcJHG 50.0/100Mixed-positive evidence70% evidence 19.9/35 Income 24.5% · PAT 100% 71% evidence 11.1/25 ROA 1.2% · ROE 1.9% · GNPA — 68% evidence 5.5/20 P/BV 1.53× · P/BV÷ROE 0.81 70% evidence 13.5/20 RS sector 6.2% · RS bench 0.6% · 1Y 28.9%0 of 7 weeks ahead to 2026-07-02 70% evidence
Exact sum: 19.9 + 11.1 + 5.5 + 13.5 = 50 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
9Invesco Ltd.IVZ 49.8/100Mixed-negative evidence60% evidence BREAKING OUT 19.1/35 Income — · PAT — 26% evidence 10.4/25 ROA 1% · ROE 2.4% · GNPA — 68% evidence 7.3/20 P/BV 0.94× · P/BV÷ROE 0.39 70% evidence 13.0/20 RS sector 8.4% · RS bench 12.4% · 1Y 54.4%8 of 12 weeks ahead 100% evidence
Exact sum: 19.1 + 10.4 + 7.3 + 13 = 49.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
10T. Rowe Price Group, Inc.TROW 49.7/100Mixed-negative evidence60% evidence BREAKING OUT 17.3/35 Income — · PAT — 26% evidence 15.7/25 ROA 2.8% · ROE 6.1% · GNPA — 68% evidence 7.5/20 P/BV 2.21× · P/BV÷ROE 0.36 70% evidence 9.2/20 RS sector -2.8% · RS bench 0.6% · 1Y 10.2%9 of 12 weeks ahead 100% evidence
Exact sum: 17.3 + 15.7 + 7.5 + 9.2 = 49.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
11Ares Management CorporationARES 48.7/100Mixed-negative evidence60% evidence BREAKING OUT 20.7/35 Income — · PAT — 26% evidence 14.1/25 ROA 1.5% · ROE 7.1% · GNPA — 68% evidence 4.8/20 P/BV 6.11× · P/BV÷ROE 0.86 70% evidence 9.1/20 RS sector -11.7% · RS bench -9.3% · 1Y -24.2%5 of 12 weeks ahead 100% evidence
Exact sum: 20.7 + 14.1 + 4.8 + 9.1 = 48.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
12StepStone Group Inc.STEP 46.6/100Thin evidence · provisional55% evidence BASING 23.2/35 Income 69.7% · PAT — 45% evidence 13.4/25 ROA 6.9% · ROE 0.5% · GNPA — 68% evidence 9.8/20 P/BV -9.31× · P/BV÷ROE — 10% evidence 0.2/20 RS sector -24.7% · RS bench -22.5% · 1Y -16.8%0 of 12 weeks ahead 100% evidence
Exact sum: 23.2 + 13.4 + 9.8 + 0.2 = 46.6 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
13Franklin Resources, Inc.BEN 46.5/100Mixed-negative evidence60% evidence LEADER 17.5/35 Income — · PAT — 26% evidence 8.8/25 ROA 0.4% · ROE 1.8% · GNPA — 68% evidence 5.8/20 P/BV 1.44× · P/BV÷ROE 0.8 70% evidence 14.4/20 RS sector 16% · RS bench 20.5% · 1Y 43.1%11 of 12 weeks ahead 100% evidence
Exact sum: 17.5 + 8.8 + 5.8 + 14.4 = 46.5 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
14Hamilton Lane IncorporatedHLNE 45.5/100Mixed-negative evidence76% evidence TURNING 15.1/35 Income 6.6% · PAT 24% 71% evidence 17.8/25 ROA 3.6% · ROE 9.6% · GNPA — 68% evidence 6.3/20 P/BV 4.75× · P/BV÷ROE 0.49 70% evidence 6.3/20 RS sector -22.9% · RS bench -21% · 1Y -34.3%1 of 12 weeks ahead 100% evidence
Exact sum: 15.1 + 17.8 + 6.3 + 6.3 = 45.5 · Decision use: Strong business, demanding price: keep it on the quality list, but require either earnings upgrades or valuation compression.
15Corebridge Financial, Inc.this pageCRBG 44.7/100Thin evidence · provisional55% evidence BREAKING OUT 19.1/35 Income 14.6% · PAT -71.3% 45% evidence 5.2/25 ROA 0% · ROE -0.5% · GNPA — 68% evidence 9.8/20 P/BV 1.01× · P/BV÷ROE — 10% evidence 10.6/20 RS sector -7.3% · RS bench -4.4% · 1Y -5.1%9 of 12 weeks ahead 100% evidence
Exact sum: 19.1 + 5.2 + 9.8 + 10.6 = 44.7 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
16Principal Financial Group, Inc.PFG 43.3/100Mixed-negative evidence60% evidence BREAKING OUT 15.9/35 Income — · PAT — 26% evidence 7.5/25 ROA 0.1% · ROE 3.6% · GNPA — 68% evidence 6.4/20 P/BV 1.91× · P/BV÷ROE 0.53 70% evidence 13.5/20 RS sector 7.3% · RS bench 11.5% · 1Y 50.4%9 of 12 weeks ahead 100% evidence
Exact sum: 15.9 + 7.5 + 6.4 + 13.5 = 43.3 · Decision use: Price leads the evidence: RS versus the benchmark is 11.5%, but earnings trajectory is weak. Wait for revenue and profit confirmation.
17Blue Owl Capital Inc.OWL 42.6/100Mixed-negative evidence60% evidence TURNING 19.5/35 Income — · PAT — 26% evidence 12.1/25 ROA 1.6% · ROE 1.9% · GNPA — 68% evidence 4.5/20 P/BV 2.94× · P/BV÷ROE 1.55 70% evidence 6.5/20 RS sector -22.2% · RS bench -20.4% · 1Y -41.4%0 of 12 weeks ahead 100% evidence
Exact sum: 19.5 + 12.1 + 4.5 + 6.5 = 42.6 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
18Brookfield Asset Management Ltd.BAM 41.6/100Mixed-negative evidence76% evidence BASING 16.2/35 Income 21.5% · PAT 10.5% 71% evidence 15.5/25 ROA 3.3% · ROE 5.3% · GNPA — 68% evidence 3.4/20 P/BV 9.38× · P/BV÷ROE 1.77 70% evidence 6.5/20 RS sector -11.6% · RS bench -8.8% · 1Y -15.2%0 of 12 weeks ahead 100% evidence
Exact sum: 16.2 + 15.5 + 3.4 + 6.5 = 41.6 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
19Equitable Holdings, Inc.EQH 37.7/100Mixed-negative evidence76% evidence BREAKING OUT 12.0/35 Income -23.4% · PAT -126% 71% evidence 12.7/25 ROA 0.3% · ROE 24.1% · GNPA — 68% evidence 3.4/20 P/BV 38.27× · P/BV÷ROE 1.59 70% evidence 9.6/20 RS sector -8.4% · RS bench -5.6% · 1Y -7.2%9 of 12 weeks ahead 100% evidence
Exact sum: 12 + 12.7 + 3.4 + 9.6 = 37.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
20TPG Inc.TPG 36.5/100Mixed-negative evidence64% evidence TURNING 16.6/35 Income 11.5% · PAT 100% 71% evidence 4.4/25 ROA -0.8% · ROE -3.4% · GNPA — 68% evidence 9.4/20 P/BV 5.73× · P/BV÷ROE — 10% evidence 6.1/20 RS sector -17.4% · RS bench -15.2% · 1Y -20.6%1 of 12 weeks ahead 100% evidence
Exact sum: 16.6 + 4.4 + 9.4 + 6.1 = 36.5 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
21KKR & Co. Inc.KKR 35.7/100Mixed-negative evidence60% evidence TURNING 16.8/35 Income — · PAT — 26% evidence 7.9/25 ROA 0.2% · ROE 2.1% · GNPA — 68% evidence 4.9/20 P/BV 2.7× · P/BV÷ROE 1.28 70% evidence 6.1/20 RS sector -16.2% · RS bench -13.9% · 1Y -24.2%0 of 12 weeks ahead 100% evidence
Exact sum: 16.8 + 7.9 + 4.9 + 6.1 = 35.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
22Brookfield CorporationBN 35.4/100Mixed-negative evidence76% evidence ASLEEP 20.1/35 Income -6.7% · PAT 100% 71% evidence 8.6/25 ROA 0.7% · ROE 0.5% · GNPA — 68% evidence 3.7/20 P/BV 2.95× · P/BV÷ROE 5.9 70% evidence 3.0/20 RS sector -13.3% · RS bench -10.3% · 1Y 3.4%1 of 12 weeks ahead 100% evidence
Exact sum: 20.1 + 8.6 + 3.7 + 3 = 35.4 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
23Apollo Global Management, Inc.APO 31.8/100Adverse evidence64% evidence ASLEEP 12.3/35 Income 28.2% · PAT -45% 71% evidence 5.2/25 ROA -0.5% · ROE -3.9% · GNPA — 68% evidence 9.7/20 P/BV 3.22× · P/BV÷ROE — 10% evidence 4.6/20 RS sector -9.9% · RS bench -7% · 1Y -6.2%4 of 12 weeks ahead 100% evidence
Exact sum: 12.3 + 5.2 + 9.7 + 4.6 = 31.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
24Blue Owl Capital CorporationOBDC 27.0/100Adverse evidence62% evidence BASING 9.4/35 Income -11% · PAT -50.5% 55% evidence 10.1/25 ROA — · ROE 0.5% · GNPA — 34% evidence 4.7/20 P/BV 0.77× · P/BV÷ROE 1.53 70% evidence 2.8/20 RS sector -19.5% · RS bench -16.9% · 1Y -21%0 of 12 weeks ahead 100% evidence
Exact sum: 9.4 + 10.1 + 4.7 + 2.8 = 27 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
25The Carlyle Group Inc.CG 25.3/100Adverse evidence64% evidence BASING 7.1/35 Income -28.9% · PAT -44% 71% evidence 6.5/25 ROA 0.3% · ROE -2.1% · GNPA — 68% evidence 9.6/20 P/BV 3.22× · P/BV÷ROE — 10% evidence 2.1/20 RS sector -18.2% · RS bench -15.9% · 1Y -18.6%0 of 12 weeks ahead 100% evidence
Exact sum: 7.1 + 6.5 + 9.6 + 2.1 = 25.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
26Pershing Square Inc.PS 56.4/100Thin evidence · provisional42% evidence ASLEEP 28.6/35 Income 68.8% · PAT 100% 71% evidence 7.8/25 ROA 1% · ROE -35.8% · GNPA — 68% evidence 10.0/20 P/BV — · P/BV÷ROE — 0% evidence 10.0/20 RS sector — · RS bench — · 1Y —0 of 2 weeks ahead 0% evidence
Exact sum: 28.6 + 7.8 + 10 + 10 = 56.4 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
27Ameriprise Financial, Inc.AMP 54.8/100Thin evidence · provisional46% evidence BREAKING OUT 16.6/35 Income — · PAT — 10% evidence 16.4/25 ROA — · ROE 17.9% · GNPA — 34% evidence 7.1/20 P/BV 6.48× · P/BV÷ROE 0.36 70% evidence 14.7/20 RS sector -0.2% · RS bench 3.2% · 1Y 9.6%4 of 12 weeks ahead 100% evidence
Exact sum: 16.6 + 16.4 + 7.1 + 14.7 = 54.8 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
28Northern Trust CorporationNTRS 51.9/100Thin evidence · provisional46% evidence LEADER 18.4/35 Income — · PAT — 10% evidence 12.5/25 ROA — · ROE 6% · GNPA — 34% evidence 8.6/20 P/BV 1.99× · P/BV÷ROE 0.33 70% evidence 12.4/20 RS sector 7% · RS bench 11.2% · 1Y 45.2%12 of 12 weeks ahead 100% evidence
Exact sum: 18.4 + 12.5 + 8.6 + 12.4 = 51.9 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
29Ares Capital CorporationARCC 38.0/100Thin evidence · provisional46% evidence BASING 16.5/35 Income — · PAT — 10% evidence 10.6/25 ROA — · ROE 1.2% · GNPA — 34% evidence 6.0/20 P/BV 0.96× · P/BV÷ROE 0.8 70% evidence 4.9/20 RS sector -13.5% · RS bench -10.6% · 1Y -12.9%0 of 12 weeks ahead 100% evidence
Exact sum: 16.5 + 10.6 + 6 + 4.9 = 38 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.

Missing observations are not scored as bad. Their missing weight lowers confidence and pulls the final score toward neutral. Financial companies use P/BV÷ROE and asset quality; PEG, industrial OPM and ROCE are excluded. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led S&P 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step curve the sector itself is placed on — basing, turning, breaking out, leader, fading, asleep — read from how many weeks running it has led S&P 500 and whether that lead is widening or shrinking. It describes where the PRICE stands, not the earnings trajectory and not a recommendation, and it is left blank for a company whose weekly history is too short or too stale to read.

16 · Frequently asked questions

Frequently asked questions

What is Corebridge Financial, Inc.'s stock price today?

Corebridge Financial, Inc. trades at $31.6, −8.4% over the past year. The company is valued at $14.0 B. The stock sits at 73% of its 52-week range of $22–$35, +10.0% versus its 200-day average. On the tape, the price is topping out, 6 weeks in. — as of 5 August 2026.

What were Corebridge Financial, Inc.'s latest quarterly results?

Corebridge Financial, Inc. reported total income of $4.0 B and a net loss of $0.1 B for the Mar 26 quarter. Earnings per share were $−0.11. The net margin was −1.5%, 17.0 pp higher than a year earlier. — as of 5 August 2026.

What is Corebridge Financial, Inc.'s revenue?

Corebridge Financial, Inc. reported revenue of $4.0 B in the Mar 26 quarter, +10.9% year on year. For the full FY25 fiscal year, revenue was $18.5 B (−1.2%). Over the last 4 years revenue compounded at −5.6% a year. — as of 5 August 2026.

What is Corebridge Financial, Inc.'s profit?

Corebridge Financial, Inc. earned $−0.1 B of net profit in the Mar 26 quarter. Full-year FY25 profit was $−0.4 B. The net margin ran −1.5% in the latest quarter. — as of 5 August 2026.

What is Corebridge Financial, Inc.'s market cap?

Corebridge Financial, Inc.'s market capitalisation is $14.0 B at a stock price of $31.6. Market cap is the share price multiplied by shares outstanding, so it is restated whenever the price moves. — as of 5 August 2026.

What is Corebridge Financial, Inc.'s P/BV ratio?

Corebridge Financial, Inc. trades at a P/BV of 1.4×, at the 52nd percentile of its own 4-year range, against a long-run median of 1.4×. This is a comparison with the stock's own history, not a value call — as of 5 August 2026.

Does Corebridge Financial, Inc. pay a dividend?

Yes — Corebridge Financial, Inc. declared $0.25 per share for Mar 26, and $0.97 per share across the last four reported quarters. The latest quarter is up 4.2% on the same quarter a year earlier. — as of 5 August 2026.

What is Corebridge Financial, Inc.'s dividend per share?

Corebridge Financial, Inc.'s most recently declared dividend is $0.25 per share for Mar 26, giving $0.97 per share over the trailing twelve months. Each figure is the amount declared for that quarter as reported, added across four quarters for the trailing total. — as of 5 August 2026.

What is Corebridge Financial, Inc.'s dividend yield?

Corebridge Financial, Inc.'s trailing dividend yield is 3.07%: $0.97 declared per share across the last four reported quarters, against a share price of $31.6. Each quarter’s figure is the amount declared for that quarter as reported, added across four quarters and divided by the latest close. — as of 5 August 2026.

Is Corebridge Financial, Inc. overvalued?

On its own history, Corebridge Financial, Inc. looks mid-range against its own history: its P/BV of 1.4× sits at the 52nd percentile of its 4-year range (long-run median 1.4×). That is a percentile read against the stock's own past, not a price opinion or a direction call. — as of 5 August 2026.

How is Corebridge Financial, Inc. performing?

Corebridge Financial, Inc. is topping out, 6 weeks in. Against the S&P 500 it has been ahead on a trailing-13-week view for 9 weeks. This describes what the data did, not a rating. — as of 5 August 2026.

What stage is Corebridge Financial, Inc. in?

Deteriorating — profit and EPS growth are shrinking (profit growth −70.4% latest against +111.5% at its 12-quarter best), ROE holding at 1.8%. The read comes from the last 12 quarters of growth (revenue growth +14.6% latest, profit growth −70.4% latest, eps growth −63.6% latest) plus the ROE curve, classified by deterministic rules — a trajectory read, not a buy or sell call — as of 5 August 2026.

Is Corebridge Financial, Inc. in an uptrend?

It is stalling — the price is topping out (week 6 of stage 3), trading +10.0% versus its 200-day average and at 73% of its 52-week range. Price stages cycle base → advance → top → decline, and the stage names where this stock sits in that cycle — as of 5 August 2026.

Is Corebridge Financial, Inc. beating the market?

On recent form, yes — Corebridge Financial, Inc. has been ahead of the S&P 500 on a trailing-13-week view for 9 straight weeks, the same metric the week-by-week ribbon on this page draws. Separately, on the cumulative view: over the last 3.9 years the stock moved +53% against the S&P 500's +100% — behind the index over the full window. — as of 5 August 2026.

Will Corebridge Financial, Inc.'s stock price go up?

This page publishes no price forecast for Corebridge Financial, Inc. What it measures instead: the stock price is $31.6, the price is topping out 6 weeks in. Its P/BV of 1.4× sits at the 52nd percentile of its own 4-year range. Direction is not something this site claims to know. — as of 5 August 2026.

Is the market betting against Corebridge Financial, Inc.?

Somewhat — short interest is 8.0% of Corebridge Financial, Inc.'s tradable float, about 4.5 days to cover at typical volumes. A moderate reading: some money is positioned against it. With no quarter-by-quarter holder register here, short interest is the cleanest crowd read we hold — as of 5 August 2026.

Is Corebridge Financial, Inc.'s loan book healthy?

We do not hold quarterly loan-book quality numbers for Corebridge Financial, Inc., so this page says that plainly. The cleanest available reads are revenue growth (−1.2% in FY25) and the net margin on it (−1.5%) — as of 5 August 2026.

Where is Corebridge Financial, Inc. in its business cycle?

Corebridge Financial, Inc.'s FY25 net margin was −2.1%, against a 5-year band of −2.1%–39.4%: the low end of its own band, which is where recoveries start when they come. The latest quarter ran −1.5%. Profitability versus a company's own long band is the cleanest cycle clock this page holds — as of 5 August 2026.

What could break the Corebridge Financial, Inc. story?

The sharpest disagreement: the price moved −8.4% in a year while annual EPS moved −118.3% — the difference is re-rating, and re-rating has to be repaid with earnings. Mechanically, two Friday closes in a row below the 200-day average would end the price trend — that is the exit rule this page tracks — as of 5 August 2026.

Is Corebridge Financial, Inc. a stock worth studying right now?

This is not investment advice. The machine read: Corebridge Financial, Inc.'s three tracks disagree. Price, valuation and the earnings engine each tell a different story — the next quarter or two settles it. The sharpest open question: whether earnings grow into a price that has already moved. Every number on this page is drawn deterministically from the raw series, with no forecasts and no price opinions — as of 5 August 2026.

Chat with this pageChat with pageChatChatGPTClaudePerplexityGoogle AI